Meisel, Andreas http://orcid.org/0000-0001-7233-5342
Annane, Djillali http://orcid.org/0000-0001-6805-8944
Vu, Tuan http://orcid.org/0000-0003-0724-0210
Mantegazza, Renato http://orcid.org/0000-0002-9810-5737
Katsuno, Masahisa http://orcid.org/0000-0001-9453-9311
Aguzzi, Rasha http://orcid.org/0000-0002-8587-7105
Frick, Glen
Gault, Laura
Howard, James F. Jr. http://orcid.org/0000-0002-7136-8617
,
Funding for this research was provided by:
Alexion, AstraZeneca Rare Disease
Charité - Universitätsmedizin Berlin
Article History
Received: 27 January 2023
Revised: 29 March 2023
Accepted: 30 March 2023
First Online: 27 April 2023
Declarations
:
: Andreas Meisel has received speaker honoraria, consulting fees, or financial research support (paid to institution) from Alexion, AstraZeneca Rare Disease, Argenx, Axunio, Grifols, Hormosan, Janssen, Merck, Octapharma, and UCB. He serves as chairman of the medical advisory board of the German Myasthenia Gravis Society. Djillali Annane has received consultancy fees from Alexion, AstraZeneca Rare Disease. Tuan Vu is the USF Site Principal Investigator for MG clinical trials sponsored by Alexion, AstraZeneca Rare Disease, argenx, Ra/UCB Pharma, Horizon/Viela Bio, Janssen/Momenta, Sanofi, Regeneron, and Cartesian Therapeutics; he receives speaker and/or consultant honoraria from Alexion, AstraZeneca Rare Disease, UCB, and argenx. Renato Mantegazza serves on advisory boards for Alexion, AstraZeneca Rare Disease, UCB, argenx, Catalyst, and Sanofi. He has received speaker’s honoraria from Alexion, AstraZeneca Rare Disease, UCB, and argenx, and consultancy fees from Catalyst. Masahisa Katsuno has received speaker honoraria from Biogen Japan, Chugai, and Eisai, and financial research support from Alexion, AstraZeneca Rare Disease, argenx, Eisai, and Mitsubishi-Tanabe. Rasha Aguzzi and Glen Frick are employees of and own stock in Alexion, AstraZeneca Rare Disease. Laura Gault was an employee of Alexion, AstraZeneca Rare Disease at the time the study and analysis were conducted. James F Howard Jr has received research support (paid to institution) from Alexion, AstraZeneca Rare Disease, argenx, Cartesian Therapeutics, the Centers for Disease Control and Prevention (Atlanta, GA, USA), the Myasthenia Gravis Foundation of America, the Muscular Dystrophy Association, the National Institutes of Health (including the National Institute of Neurological Disorders and Stroke, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases), PCORI, Ra Pharmaceuticals (now UCB Pharma), and Takeda Pharmaceuticals; honoraria from Alexion, AstraZeneca Rare Disease, argenx, Immunovant Inc., Ra Pharmaceuticals (now UCB Pharma), Regeneron Pharmaceuticals, Sanofi US, and Viela Bio Inc. (now Horizon Therapeutics); and non-financial support from Alexion, AstraZeneca Rare Disease, argenx, Ra Pharmaceuticals (now UCB Pharma), and Toleranzia AB.
: The trial protocol was approved by the independent ethics committee or institutional review board at each participating institution. The trial was conducted in accordance with the provisions of the World Medical Association Declaration of Helsinki, the International Conference on Harmonisation E6 Guidelines for Good Clinical Practice, and all applicable regulatory requirements.
: Informed consent was obtained from all individual participants included in the study.